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ABSTRACT
The concept of “atopic march” has been well appreciated both by physicians and by dermatologists; eczema
(atopic dermatitis) often precedes the development of airway diseases such as asthma and allergic rhinitis in
atopic subjects. However, the underlying mechanisms for atopic march are less elucidated. It has been con-
ceived that genetic susceptibility to atopy determines the phenotype of allergic diseases progressive from the
skin to the airways, but recent discovery of filaggrin gene mutations that disturb the barrier function of the skin
in patients with asthma and eczema now suggests the crucial role of epicutaneous sensitization as a precur-
sory event for the development of asthma. In the present review, we describe updated genetic and immunologi-
cal evidences that suggest the relationship between skin barrier-related molecules and the pathology of
asthma.
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INTRODUCTION
Atopic asthma develops often in childhood with the
sensitization of host immune system to the specific al-
lergens derived from insects, fungi, animals, low mo-
lecular weight chemicals, et al. The route for the al-
lergen to evade into the body is variable from the air-
ways, the gastrointestinal tract, to the skin (epicuta-
neous sensitization). Eczema (atopic dermatitis)
often precedes airway diseases such as asthma and
allergic rhinitis in a substantial proportion of patients,
in whom epicutaneous sensitization should be a cru-
cial precursory process for the development of airway
diseases.
Intact epidermal barrier protects the immune sys-
tem from the exposure to exogenous allergens that
eventually cause unfavorable allergic reactions, while
impaired skin barrier, either mechanically or func-
tionally, can allow the allergens to penetrate into the
sub-epidermal layer of the skin and make the host
susceptible to atopic diseases. Recent progress in the
genetics and the immunology further supports the
role of skin barrier-related molecules in the patho-
physiology of allergic diseases in the airways, such as
asthma. In the present review, we focus on the role of
genetic mutations in filaggrin, an essential protein for
the skin barrier system, on the susceptibility to
asthma, and also update the immunological aspects of
epicutaneous sensitization in the development of al-
lergic airway inflammation.
GENETIC EVIDENCES SUGGEST THAT THE
MOLECULE(S) RELATED TO SKIN BAR-
RIER FUNCTION IS ASSOCIATED WITH THE
SUSCEPTIBILITY TO ASTHMA (Table 1)
It has been more than 20 years since Cookson and
his colleagues published the first evidence that there
is a linkage between specific genetic loci (chromo-
some 11) and atopyasthma. A number of studies
have been performed on the field of asthma genetics
since then, however, our knowledge about asthma
susceptibility genes is still limited. The reported asso-
ciations between the “candidate” genes and asthma
are not reproducible in many cases, while laborious,
but less biased, genome-wide approaches have only
suggested a few genes with unknown biological and
pathological functions, such ADAM33, CYFIP2,
DPP10, HLA-G, GPRA, and PHF11.1-6 ADAM33 on
chromosome 20p13 has been one of the most exten-
sively studied genes, but a number of the critical
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Table　1　Comparison of three representative asthma-susceptibility genes
ADAM33 Filaggrin ORMDL3
Protein expression bronchial smooth muscle cells cornifi ed layer of the skin unknown
molecular function unknown skin burrier function lipid synthesis
role in the physiology of asthma airway remodeling ? allergen invasion ? unknown
Gene mutation odds ratio 1.2-1.5 3.29† 1.44
number of populations reproducible 9 >20 >10
effects on expression or function of 
the protein
unknown null mutations unknown
† asthma accompanied with eczema.
questions are still unanswered; which mutation(s) in
ADAM33 is crucial for the development of asthma,
what kind of changes in the gene expression or the
protein function are caused by the mutation(s), what
is the biological function of ADAM33, and how the
mutant ADAM33 gene relates to the pathology of
asthma.
To our surprise, a major breakthrough in the ge-
netics of asthma has been brought by a simple case-
control study for atopic dermatitis with a candidate
gene, filaggrin, on chromosome 1q21. Two null muta-
tions in this gene, R501X and 2282del4, had been
identified as the susceptibility gene for icthyosis vul-
garis using classic linkage analysis and positional
cloning.7 R501X mutation replaces the nucleotide se-
quence coding arginine with stop codon, and
2282del4 mutation causes frame shift, also resulting
in the premature termination of translation. The re-
searchers who identified these mutations noticed that
the heterozygous carriers of filaggrin gene mutations
were more likely to exhibit atopic dermatitis. Using
three modest size of cohorts from Iceland, Scotland,
and Netherlands, they demonstrated that R501X and
2282del4 mutations were more common in the sub-
jects with atopic dermatitis than in control subjects
with the OR of 3.4.8 Surprisingly, more than 20 stud-
ies have already replicated the association between
atopic dermatitis and filaggrin gene mutations with
the OR of 3.12 (95% confidence interval, 2.57-3.79).9
The original work has suggested that filaggrin
gene mutations are more common in patients with
the combination of atopic dermatitis and asthma.8
Successive studies have further confirmed a strong
association between filaggrin gene mutations and
atopic asthma accompanied with eczema. A meta-
analysis of 14 studies demonstrates that the OR of
filaggrin gene mutations is 1.48 (95% confidence in-
terval, 1.32-1.66) for asthma, and 3.29 (95% confi-
dence interval, 2.84-3.82) for eczema-associated
asthma, whereas there is no association with asthma
unaccompanied with eczema (OR 1.11, 95% confi-
dence interval, 0.88-1.41).9 The association is more
evident in childhood asthma; the risk developing
asthma at later stage is higher in children with ec-
zema in the first year of life and the combined filag-
grin mutations.10 Another report demonstrates that
filaggrin variants increase the risk of developing re-
current wheeze and asthma within the first one and
half year of life.11 Filaggrin gene mutations also affect
the severity of asthma; individuals with filaggrin null
alleles carry a significantly increased risk of exacer-
bations requiring hospital admissions, courses of oral
steroids, or experiencing school absences11,12. Filag-
grin is required for the maintenance of skin barrier
function in the cornified layer of the skin as discussed
in detail in the review by Osawa et al. in this journal.
The association with filaggrin gene mutations is the
first solid evidence that skin barrier function is impor-
tant for the development of asthma in the childhood.
Another pediatric asthma-susceptibility gene,
ORMDL3 on chromosome 17q21, has been identified
by a genome-wide association study.13 A meta-
analysis suggests the OR of 1.44 (95% confidence in-
terval, 1.35-1.54) for the association between
ORMDL3 and asthma.14 Recent studies using yeasts
and cultured cells have clarified the functions of
ORMDL3 as the regulator of sphingolipid synthesis
and unfolded protein response in endoplasmic reticu-
lum.15,16 Interestingly, integrity of skin barrier de-
pends on the presence of adequate amount of cera-
mide and sphingosine, implying that ORMDL3 muta-
tions may also be associated with disturbance of skin
barrier function.
IMMUNOLOGICAL INTERACTIONS OF AL-
LERGENS AND DANGER SIGNALS WITH
THE SKIN MODIFY THE DEVELOPMENT OF
ATOPY AND ASTHMA (Table 2)
It has long been speculated that the proteases in al-
lergens such as mites, fungi, or pollen digest the epi-
thelial barrier-related protein and assist allergenic
proteinpeptide to enter into the sub-epithelial layer.
In fact, proteolytic enzymes often act as the key com-
ponents of allergens, for example, a cysteine protease
(Der p1) in house dust mite (Dermatophagoides ptero-
nyssinus),17,18 serine proteases (Asp f13 and f18), an
aspartic protease (Asp f10), and a metalloprotease
(Asp f5) in Aspergillus fumigatus. Protease activities in
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Table　2　The immune responses induced by the combination of allergen, danger signal, and route of allergen entry
Allergen Danger signal Route of allergen entry Th2 Th17
OVA airway +/- +/-
OVA alum peritoneal cavity ++ +/-
OVA lipopolysaccharide airway ++ +
HDM / Fungus protease airway ++ +
OVA mechanical damage? skin ++ +
OVA, ovalbumin; HDM, House dust mite extract.
Fig.　1　Interaction of allergen, danger signals, and barrier-related molecules during the 
sensitization and following immunological responses to allergen. Simple antigen (such as 
ovalbumin) application does not provoke asthmatic phenotypes. Co-administration of dan-
ger signals such as protease, LPS, or mechanical damage of epithelial/epidermal layer 
(①) and the altered skin barrier functions due to the genetic mutation of barrier-related 
molecules (fi laggrin et al.) (②) induces the release of infl ammatory mediators including 
TSLP and activates antigen-presenting cells (③), leading to Th2 and Th17 cell differentia-
tion and activation (④). Th2 and Th17 cells (⑤) contribute to the development of airway 
hyperresponsiveness.
Danger signal ①
Protease, LPS,
mechanical damage
Altered  Barrier Functions ②
Filaggrin gene mutation etc.
Antigen
Th2 Th17
Antigen-presenting
cell activation ③
T cell activation ④
Airway hyperresponsiveness
and inflammation ⑤
TSLP etc.
Alum
IL-23 etc.
the allergens appear to be crucial for the allergic sen-
sitization process; repeated administration of mite or
fungus extracts into the airway easily induces airway
hyperresponsiveness and eosinophilic inflamma-
tion,19-22 whereas an innocent extrinsic protein with-
out proteolytic activity such as ovalbumin (OVA) fails
to cause these phenotypes in the absence of adjuvant.
In contrast, epicutaneous exposure to OVA alone fol-
lowed by airway exposure, without alum or other ad-
juvant, induces elevated serum IgE levels, Th2 cy-
tokine production, nasal symptoms, and airway hy-
perresponsiveness.23-25
In the last decade, however, another hypothesis on
the interaction between the proteases and epithelial
epidermal barrier during allergic sensitization has
emerged. An intraperitoneal injection of OVA, al-
though epidermal barrier is bypassed, is insufficient
for the sensitization, and the co-injection of an adju-
vant, alum, is required to provoke a strong Th2-type
inflammation and airway hyperresponsiveness. In
this setting, alum acts as a danger signal that alarms
the antigen-presenting cells such as dendritic cells,
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resulting in the formulation of NLRP3 inflammasome
and activation of caspase-1 that matures IL-1β and IL-
18 into the biologically-active forms.26,27 Proteases in
the allergens may similarly serve as a danger signal
to facilitate the immune response. Other than alum or
proteases, addition of small amount of lipopolysaccha-
ride or Der p2 in house dust mite that is structurally
related to LPS promotes the sensitization.28,29
Mechanical damage of the skin such as scratching
may serve as the danger signal during the epicutane-
ous sensitization, but little is known about this proc-
ess. Meanwhile, the molecules that may transduce
the signals from the skin to the airways following
epicutaneous sensitization are getting clarified in the
past few years (Fig. 1). The airway responses in-
duced by epicutaneous sensitization (without alum)
are mediated by Th2 cytokines, CCR3 chemokines,
and STAT6 signaling, similarly to the response
caused by intraperitoneal sensitization (with
alum).30,31 However, the contribution of IL-4 and IL-
13, which is critical for the intraperitoneal sensitiza-
tion protocol, is less important for the epicutaneous
sensitization.24,32,33 As we previously reported, OVA-
specific IgG1 response occurs more robustly in Th2-
prone BALBc mice, but airway inflammation and hy-
perresponsiveness is more prominent in C57BL6
mice when sensitized through the skin.24 One of the
characteristic features for the epicutaneous exposure
of allergens is successive Th17-type response with
the increased production of IL-17A and IL-23 in the
skin, lymph nodes, and spleen, in addition to Th2-
type reaction.34 Importantly, flaky tail mice with a mu-
tation in the filaggrin gene demonstrate an exagger-
ated Th17 response in response to epicutaneous ap-
plication of ovalbumin to shaved skin.35 There are
lines of evidence suggesting that IL-17A and Th17-
type response may be related to the development of
severe asthma; expression of IL-17A in the airway of
asthma patients is proportional to the severity of the
disease.19,36 Th17 cells instilled into the airways pro-
mote the airway hyperresponsiveness synergistically
with Th2 cells.37 Taken together, Th17 cytokines are
essential for the airway pathology induced by epicuta-
neous sensitization.
Thymic stromal lymphopoietin (TSLP) is another
mediator possibly released from the skin or other or-
gans upon epithelialepidermal damage. Disruption
of epithelial barrier, either mechanically or function-
ally, causes TSLP release.38-40 Once it is released
from epithelialepidermal cells, TSLP leads to Th2-
deviated inflammation through antigen presenting
cells, T cells, B cells or mast cells.41,42 Cutaneous in-
jection of TSLP alone causes Th2-mediated lung in-
flammation and airway hyper-responsiveness.39,43 It
is, however, still undetermined how the impaired
skin barrier is related to the modulation of TSLP syn-
thesis.
CONCLUSION
Although asthma can now be controlled with inhaled
corticosteroids and other medications in most cases,
some asthmatics, including patients with early-onset
atopic asthma, develop the disease refractory to cur-
rent treatment. Furthermore, even an early introduc-
tion of therapy with inhaled corticosteroids in child-
hood is unable to cure or prevent the development of
asthma, showing another limitation of the current
treatment strategy of asthma. The discovery of filag-
grin gene mutations in patients with eczema-
associated asthma re-vitalized the old concept of
“atopic march”. We hope that detailed analysis of the
pathway for the allergic phenotypes to shift from the
skin to the airways would possibly leads to the identi-
fication of novel tactics to prevent and treat allergic
airway diseases.
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